# AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Source: https://onco.cc/trials/nct05247684/  
OnCo record `nct05247684` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ivonescimab, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, active and no longer recruiting.

## Summary

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC is a phase 2 interventional study registered as NCT05247684 by Akeso, with 90 participants enrolled, started 2022-02-20 and due to reach its primary completion in 2025-08-18. Interventions recorded: AK112, Carboplatin, Cisplatin, Paclitaxel. Conditions listed: Resectable Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05247684
- Phase: 2
- Setting: Phase II Clinical Study of AK112, an Anti-PD-1 and VEGF Bispecific Antibody, Alone or in Combination With Chemotherapy for the Neoadjuvant/Adjuvant Treatment of Resectable Non-small Cell Lung Cancer
- Sponsor: Akeso
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT05247684: https://clinicaltrials.gov/study/NCT05247684

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05247684.json